Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.O)

SPPI.O on Nasdaq

9.45USD
22 Sep 2017
Change (% chg)

$-0.36 (-3.67%)
Prev Close
$9.81
Open
$9.85
Day's High
$9.90
Day's Low
$9.03
Volume
1,947,261
Avg. Vol
851,539
52-wk High
$10.77
52-wk Low
$3.21

Select another date:

Mon, Aug 14 2017

BRIEF-Spectrum Pharma starts phase 3 qapzola trial

* Spectrum pharmaceuticals announces initiation of the registrational phase 3 trial of qapzola™ (apaziquone) in patients with non-muscle invasive bladder cancer (nmibc)

BRIEF-Spectrum Pharma enters into an at market issuance sales agreement

* Spectrum Pharmaceuticals Inc - on August 4, 2017, co entered into an at market issuance sales agreement - sec filing

BRIEF-Spectrum Pharmaceuticals Q2 loss per share $0.26

* Spectrum Pharmaceuticals reports second quarter 2017 financial results and pipeline update

BRIEF-Spectrum Pharmaceuticals announces ‍enrollment in Rolontis phase 3 advance pivotal study​

* Spectrum Pharmaceuticals Inc - ‍enrollment with 405 patients randomized in rolontis phase 3 advance pivotal study​

BRIEF-Spectrum Pharmaceuticals says stockholders did not approve by advisory vote executive compensation at annual meeting

* Spectrum Pharmaceuticals Inc - stockholders did not approve by advisory vote executive compensation at annual meeting Source text: (http://bit.ly/2sHq6yo) Further company coverage:

BRIEF-Spectrum Pharmaceuticals reports Q1 loss per share $0.29

* Spectrum Pharmaceuticals reports first quarter 2017 financial results and pipeline update

BRIEF-Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib

* Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib in non-small cell lung cancer patients with EGFR exon 20 insertion mutations

Select another date: